We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0JDK market cap is 4.16B. The company's latest EPS is USD -1.7351 and P/E is -6.65.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 1.19M |
| Operating Income | -206.87M | -261.94M | -342.7M | -398.88M | -460.56M |
| Net Income | -197.56M | -259.58M | -342.25M | -395.89M | -444.04M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 344.66M | 768.46M | 777.33M | 663.98M | 780.35M |
| Total Liabilities | 45.68M | 111.96M | 155.67M | 164.34M | 195.74M |
| Total Equity | 298.97M | 656.5M | 621.66M | 499.64M | 584.61M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -158.89M | -205.13M | -227.94M | -292.76M | -361.82M |
| Investing | 90.03M | -317.85M | 132k | 256.46M | -155.24M |
| Financing | 6.13M | 576.42M | 239.27M | 190.15M | 462.96M |
| Market Cap | 4.16B |
| Price to Earnings Ratio | -6.65 |
| Price to Sales Ratio | 2.51k |
| Price to Cash Ratio | 25.71 |
| Price to Book Ratio | 5.05 |
| Dividend Yield | - |
| Shares Outstanding | 255.92M |
| Average Volume (1 week) | 11.73k |
| Average Volume (1 Month) | 7.08k |
| 52 Week Change | 0.00% |
| 52 Week High | 16.25 |
| 52 Week Low | 16.25 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Iovance Biotherapeutics Inc |
| Address |
2140 s dupont hwy camden, delaware 19934 |
| Website | https://www.iovance.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
